SCHEMBL10074732

SCHEMBL10074732

CC(C)(CNC(=O)CC(N)Cc1cc(F)c(F)c(F)c1F)CNC(=O)C(O)C(N)COCc1ccccc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP12 P39900 1/20 0.38
DPP4 P27487 8/20 0.37
DPP8 Q6V1X1 1/20 0.37
DPP7 Q9UHL4 1/20 0.37
ADRB2 P07550 2/20 0.36
ADRB1 P08588 2/20 0.36
ADRB3 P13945 2/20 0.36
LAP3 P28838 2/20 0.35
ANPEP P15144 1/20 0.35
RNPEP Q9H4A4 1/20 0.35
DNPEP Q9ULA0 1/20 0.35
REN P00797 3/20 0.35
CTSS P25774 1/20 0.33
TACR1 P25103 1/20 0.33
PSMB11 A5LHX3 1/20 0.33
PSMD11 O00231 1/20 0.33
PSMD12 O00232 1/20 0.33
PSMD14 O00487 1/20 0.33
PSMA7 O14818 1/20 0.33
PSMD3 O43242 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10074269 0.92 DPP4 (0.45) DPP4DPP8DPP7
SCHEMBL10077523 0.89 LAP3 (0.38) MMP12ADRB2ADRB1ADRB3LAP3
SCHEMBL10074326 0.88 DPP4 (0.41) DPP4DPP8DPP7REN
SCHEMBL10074457 0.88 DPP4 (0.41) DPP4DPP8DPP7REN
SCHEMBL10074281 0.80 DPP4 (0.41) DPP4DPP8DPP7REN
SCHEMBL10074280 0.80 REN (0.42) DPP4DPP8DPP7REN
SCHEMBL10075001 0.80 REN (0.42) DPP4DPP8DPP7REN
SCHEMBL10074129 0.79 REN (0.37) DPP4DPP7ADRB2ADRB1ADRB3
SCHEMBL10074716 0.79 REN (0.37) DPP4DPP7ADRB2ADRB1ADRB3
SCHEMBL10078267 0.79 REN (0.37) DPP4DPP7ADRB2ADRB1ADRB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2418196-A1 Dual alanyl-aminopeptidase and dipeptidyl-peptidase IV inhibitors IMTM GmbH (DE) 2012-02-15 EP disclosed
US-20120028995-A1 NOVEL COMPOUNDS FOR MEDICAL USE AS PEPTIDASE EFFECTORS IMTM GMBH (DE) 2012-02-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120028995-A1 NOVEL COMPOUNDS FOR MEDICAL USE AS PEPTIDASE EFFECTORS SERPINB1, CMA1, CPA3 MMP12 8/4885DPP4 121/4885DPP8 127/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.